{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:46:14Z","timestamp":1792853174372,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009399","name":"Peking University Third Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","award":["BYSYZD2021002"],"award-info":[{"award-number":["BYSYZD2021002"]}],"id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.dmd.2025.100181","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:11:30Z","timestamp":1760001090000},"page":"100181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Methotrexate gene polymorphisms link to toxicity but not pharmacokinetics in Chinese adults and adolescents with acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"53","author":[{"given":"Hao","family":"Bing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qixian","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4968-6045","authenticated-orcid":false,"given":"Libo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.dmd.2025.100181_bib1","doi-asserted-by":"crossref","first-page":"e508","DOI":"10.1016\/S1470-2045(13)70452-2","article-title":"Management of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013","volume":"14","author":"Yeoh","year":"2013","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.dmd.2025.100181_bib2","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2008-06-164863","article-title":"Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century","volume":"113","author":"Pulte","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.dmd.2025.100181_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085554","article-title":"Survival of adults with acute lymphoblastic leukemia in Germany and the United States","volume":"9","author":"Pulte","year":"2014","journal-title":"PLoS One"},{"issue":"18","key":"10.1016\/j.dmd.2025.100181_bib4","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJM198311033091805","article-title":"The pharmacology and clinical use of methotrexate","volume":"309","author":"Jolivet","year":"1983","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.dmd.2025.100181_bib5","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.6004\/jnccn.2015.0153","article-title":"Acute lymphoblastic leukemia, version 2.2015","volume":"13","author":"Alvarnas","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.dmd.2025.100181_bib6","first-page":"306","article-title":"Association of plasma methotrexate, neutropenia, hepatic dysfunction, nausea\/vomiting and oral mucositis in children with cancer","volume":"17","author":"Cheng","year":"2008","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"10","key":"10.1016\/j.dmd.2025.100181_bib7","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s00432-012-1214-2","article-title":"Clinical relations of methotrexate pharmacokinetics in the treatment for pediatric osteosarcoma","volume":"138","author":"Hegyi","year":"2012","journal-title":"J Cancer Res Clin Oncol"},{"issue":"12","key":"10.1016\/j.dmd.2025.100181_bib8","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard","year":"2016","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.dmd.2025.100181_bib9","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1080\/02841860510029770","article-title":"High dose methotrexate in adult patients with osteosarcoma: clinical and pharmacokinetic results","volume":"44","author":"Comandone","year":"2005","journal-title":"Acta Oncol"},{"issue":"6","key":"10.1016\/j.dmd.2025.100181_bib10","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00280-019-03966-4","article-title":"Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patients","volume":"84","author":"Kawakatsu","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2025.100181_bib11","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1634\/theoncologist.11-6-694","article-title":"Understanding and managing methotrexate nephrotoxicity","volume":"11","author":"Widemann","year":"2006","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.dmd.2025.100181_bib12","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1002\/cncr.20255","article-title":"High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma","volume":"100","author":"Widemann","year":"2004","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.dmd.2025.100181_bib13","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/cts.12879","article-title":"Effect of SLCO1B1 polymorphisms on high-dose methotrexate clearance in children and young adults with leukemia and lymphoblastic lymphoma","volume":"14","author":"Schulte","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"7","key":"10.1016\/j.dmd.2025.100181_bib14","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2174\/1389200220666190701094756","article-title":"Influence of the OATP polymorphism on the population pharmacokinetics of methotrexate in Chinese patients","volume":"20","author":"Wang","year":"2019","journal-title":"Curr Drug Metab"},{"issue":"3","key":"10.1016\/j.dmd.2025.100181_bib15","first-page":"168","article-title":"Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis","volume":"65","author":"Tian","year":"2007","journal-title":"Bull NYU Hosp Jt Dis"},{"issue":"7","key":"10.1016\/j.dmd.2025.100181_bib16","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1007\/s13277-015-3602-0","article-title":"Gene polymorphisms in the folate metabolism and their association with MTX-related adverse events in the treatment of ALL","volume":"36","author":"Chen","year":"2015","journal-title":"Tumour Biol"},{"issue":"19","key":"10.1016\/j.dmd.2025.100181_bib17","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1016\/S0021-9258(18)91984-8","article-title":"Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell","volume":"243","author":"Goldman","year":"1968","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.dmd.2025.100181_bib18","doi-asserted-by":"crossref","first-page":"822","DOI":"10.2174\/138920012800840400","article-title":"Intracellular disposition of methotrexate in acute lymphoblastic leukemia in children","volume":"13","author":"de Beaumais","year":"2012","journal-title":"Curr Drug Metab"},{"issue":"3","key":"10.1016\/j.dmd.2025.100181_bib19","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1172\/JCI112088","article-title":"Polyglutamation of methotrexate. Is methotrexate a prodrug?","volume":"76","author":"Chabner","year":"1985","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.dmd.2025.100181_bib20","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S0026-895X(24)13274-9","article-title":"Characterization of human cellular gamma-glutamyl hydrolase","volume":"53","author":"Rhee","year":"1998","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.dmd.2025.100181_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105371","article-title":"Interaction of nobiletin with methotrexate ameliorates 7-OH methotrexate-induced nephrotoxicity through endoplasmic reticulum stress-dependent PERK\/CHOP signaling pathway","volume":"165","author":"Song","year":"2021","journal-title":"Pharmacol Res"},{"issue":"23","key":"10.1016\/j.dmd.2025.100181_bib22","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1182\/blood-2010-01-256958","article-title":"The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number","volume":"115","author":"Gregers","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.dmd.2025.100181_bib23","first-page":"770","article-title":"[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]","volume":"52","author":"Zhang","year":"2014","journal-title":"Zhonghua Er Ke Za Zhi"},{"issue":"1","key":"10.1016\/j.dmd.2025.100181_bib24","article-title":"Association of ABCC2 -24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia","volume":"9","author":"Liu","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.dmd.2025.100181_bib25","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.clinthera.2012.06.022","article-title":"ABCB1 C3435T genetic polymorphism on population pharmacokinetics of methotrexate after hematopoietic stem cell transplantation in Korean patients: a prospective analysis","volume":"34","author":"Kim","year":"2012","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.dmd.2025.100181_bib26","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3892\/ol.2014.2175","article-title":"Effect of folylpolyglutamate synthase A22G polymorphism on the risk and survival of patients with acute lymphoblastic leukemia","volume":"8","author":"Gomez-Gomez","year":"2014","journal-title":"Oncol Lett"},{"key":"10.1016\/j.dmd.2025.100181_bib27","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0378-1119(03)00807-2","article-title":"Identification of single nucleotide polymorphisms in the human gamma-glutamyl hydrolase gene and characterization of promoter polymorphisms","volume":"319","author":"Chave","year":"2003","journal-title":"Gene"},{"issue":"1","key":"10.1016\/j.dmd.2025.100181_bib28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/BS9.0000000000000142","article-title":"Effects of genetic polymorphisms on methotrexate levels and toxicity in Chinese patients with acute lymphoblastic leukemia","volume":"5","author":"Hao","year":"2023","journal-title":"Blood Sci"},{"issue":"1","key":"10.1016\/j.dmd.2025.100181_bib29","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1475-2867-13-107","article-title":"FPGS rs1544105 polymorphism is associated with treatment outcome in pediatric B-cell precursor acute lymphoblastic leukemia","volume":"13","author":"Liu","year":"2013","journal-title":"Cancer Cell Int"},{"issue":"8","key":"10.1016\/j.dmd.2025.100181_bib30","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/FPC.0000000000000069","article-title":"Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia","volume":"24","author":"Zgheib","year":"2014","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"10.1016\/j.dmd.2025.100181_bib31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/08880018.2013.870625","article-title":"Association of -24CT, 1249GA, and 3972CT ABCC2 gene polymorphisms with methotrexate serum levels and toxic side effects in children with acute lymphoblastic leukemia","volume":"31","author":"Sharifi","year":"2014","journal-title":"Pediatr Hematol Oncol"},{"issue":"10","key":"10.1016\/j.dmd.2025.100181_bib32","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/FPC.0b013e328343dd93","article-title":"PharmGKB summary: methotrexate pathway","volume":"21","author":"Mikkelsen","year":"2011","journal-title":"Pharmacogenet Genomics"},{"issue":"9","key":"10.1016\/j.dmd.2025.100181_bib33","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.6004\/jnccn.2021.0042","article-title":"Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Brown","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"10.1016\/j.dmd.2025.100181_bib34","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00431-006-0189-x","article-title":"Population clinical pharmacology of children: modelling covariate effects","volume":"165","author":"Anderson","year":"2006","journal-title":"Eur J Pediatr"},{"issue":"10","key":"10.1016\/j.dmd.2025.100181_bib35","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1038\/s41401-022-00892-9","article-title":"Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation","volume":"43","author":"Liu","year":"2022","journal-title":"Acta Pharmacol Sin"},{"issue":"4","key":"10.1016\/j.dmd.2025.100181_bib36","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s002770050160","article-title":"High-dose methotrexate in the treatment of adult acute lymphoblastic leukemia","volume":"72","author":"Gokbuget","year":"1996","journal-title":"Ann Hematol"},{"issue":"12","key":"10.1016\/j.dmd.2025.100181_bib37","first-page":"2561","article-title":"Methotrexate infusions and intensive supportive care in the management of children with acute lymphocytic leukemia: follow-up report","volume":"27","author":"Djerassi","year":"1967","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.dmd.2025.100181_bib38","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/028418698429586","article-title":"Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia\u2014a logistic regression analysis","volume":"37","author":"Rask","year":"1998","journal-title":"Acta Oncol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100181_bib39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/pho.21.1.77.83","article-title":"Hemostatic side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia","volume":"21","author":"Fisgin","year":"2004","journal-title":"Pediatr Hematol Oncol"},{"issue":"2","key":"10.1016\/j.dmd.2025.100181_bib40","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/sj.bjc.6601472","article-title":"Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas","volume":"90","author":"Ferreri","year":"2004","journal-title":"Br J Cancer"},{"issue":"11-12","key":"10.1016\/j.dmd.2025.100181_bib41","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s00439-019-02081-x","article-title":"The genetic landscape of the human solute carrier (SLC) transporter superfamily","volume":"138","author":"Schaller","year":"2019","journal-title":"Hum Genet"},{"issue":"4","key":"10.1016\/j.dmd.2025.100181_bib42","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1158\/1078-0432.CCR-12-2080","article-title":"Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice","volume":"19","author":"van de Steeg","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"2-3","key":"10.1016\/j.dmd.2025.100181_bib43","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.mam.2012.10.009","article-title":"The SLCO (former SLC21) superfamily of transporters","volume":"34","author":"Hagenbuch","year":"2013","journal-title":"Mol Aspects Med"},{"issue":"6","key":"10.1016\/j.dmd.2025.100181_bib44","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1182\/blood-2012-08-452839","article-title":"Genome-wide study of methotrexate clearance replicates SLCO1B1","volume":"121","author":"Ramsey","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.dmd.2025.100181_bib45","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/rheumatology\/ken073","article-title":"Reduced folate carrier polymorphism determines methotrexate uptake by B cells and CD4+ T cells","volume":"47","author":"Baslund","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.dmd.2025.100181_bib46","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11095-007-9407-0","article-title":"Impaired clearance of methotrexate in organic anion transporter 3 (Slc22a8) knockout mice: a gender specific impact of reduced folates","volume":"25","author":"VanWert","year":"2008","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.dmd.2025.100181_bib47","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/FPC.0b013e32835c3b24","article-title":"Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia","volume":"23","author":"Lopez-Lopez","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.dmd.2025.100181_bib48","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.biopha.2018.04.122","article-title":"Puerarin improves methotrexate-induced renal damage by up-regulating renal expression of Oat1 and Oat3 in vivo and in vitro","volume":"103","author":"Liu","year":"2018","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"10.1016\/j.dmd.2025.100181_bib49","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/tpj.2014.81","article-title":"Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia","volume":"15","author":"Gregers","year":"2015","journal-title":"Pharmacogenomics J"},{"issue":"4","key":"10.1016\/j.dmd.2025.100181_bib50","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/jcph.1349","article-title":"Population pharmacokinetic study and individual dose adjustments of high-dose methotrexate in Chinese pediatric patients with acute lymphoblastic leukemia or osteosarcoma","volume":"59","author":"Hui","year":"2019","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.dmd.2025.100181_bib51","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.2165\/00003088-200645120-00007","article-title":"Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia","volume":"45","author":"Aumente","year":"2006","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.dmd.2025.100181_bib52","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/tpj.2012.37","article-title":"Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy","volume":"13","author":"Simon","year":"2013","journal-title":"Pharmacogenomics J"},{"issue":"3","key":"10.1016\/j.dmd.2025.100181_bib53","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/cpt.1957","article-title":"MTXPK.org: A clinical decision support tool evaluating high-dose methotrexate pharmacokinetics to inform post-infusion care and use of glucarpidase","volume":"108","author":"Taylor","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100181_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.701452","article-title":"Population pharmacokinetics of high-dose methotrexate in Chinese pediatric patients with acute lymphoblastic leukemia","volume":"12","author":"Gao","year":"2021","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2025.100181_bib55","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/FTD.0b013e31823615e1","article-title":"A population pharmacokinetic\/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma","volume":"33","author":"Johansson","year":"2011","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10.1016\/j.dmd.2025.100181_bib56","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13318-021-00737-6","article-title":"A systematic review of population pharmacokinetic models of methotrexate","volume":"47","author":"Zhang","year":"2022","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"2","key":"10.1016\/j.dmd.2025.100181_bib57","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/bcp.14160","article-title":"Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumours","volume":"86","author":"Panetta","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.dmd.2025.100181_bib58","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.xphs.2018.01.004","article-title":"Population pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma","volume":"107","author":"Mei","year":"2018","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.dmd.2025.100181_bib59","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/phar.2379","article-title":"Comparison of body size, morphomics, and kidney function as covariates of high-dose methotrexate clearance in obese adults with primary central nervous system lymphoma","volume":"40","author":"Pai","year":"2020","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.dmd.2025.100181_bib60","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/CAD.0b013e3282f21376","article-title":"High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy","volume":"19","author":"Dupuis","year":"2008","journal-title":"Anticancer Drugs"},{"issue":"10","key":"10.1016\/j.dmd.2025.100181_bib61","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s00228-011-1046-z","article-title":"Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma","volume":"67","author":"Faganel Kotnik","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.dmd.2025.100181_bib62","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/jcph.1252","article-title":"A pharmacokinetic and pharmacogenetic analysis of osteosarcoma patients treated with high-dose methotrexate: data from the OS2006\/Sarcoma-09 Trial","volume":"58","author":"Lui","year":"2018","journal-title":"J Clin Pharmacol"}],"updated-by":[{"DOI":"10.1016\/j.dmd.2026.100236","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000}},{"DOI":"10.1016\/j.dmd.2026.100236","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000}}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625094905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625094905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T09:47:37Z","timestamp":1773913657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955625094905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":62,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0090955625094905"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100181","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Methotrexate gene polymorphisms link to toxicity but not pharmacokinetics in Chinese adults and adolescents with acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100181","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100181"}}